Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
3
×
Tags
boston blog main
3
×
life sciences
national blog main
biotech
boston top stories
clinical trials
investing
national top stories
san francisco
san francisco blog main
san francisco top stories
startups
akcea therapeutics
alphabet
ame cloud ventures
american diabetes association
anylam pharmaceuticals
broad institute of harvard and mit
brook byers
cardiomyopathy
charles chu
clostridium difficile
colleen cutcliffe
computational biology
crispr
crispr cas14
deals
decheng capital
diabetes type 2
diagnostic
drugs
fda
google
infectious disease
inflammatory bowel disease
inotersen
khosla ventures
kleiner perkins
mammoth biosciences
mayfield
What
available
3
×
today
ago
akcea
alnylam
amyloidosis
approved
attr
balance
based
battle
big
bio
biome
biosciences
blood
cas
cheaper
crispr
debilitating
develop
diabetes
diagnostics
disease
drug
expects
eyes
faster
fda
food
genetic
healthy
hormone
include
intended
launch
leads
levels
mammoth
medical
Language
unset
Current search:
available
×
photo
×
" boston blog main "
×
@xconomy.com
4 years ago
With $45M, Mammoth Bio Expects Big Things From Tiny CRISPR Cas14
@xconomy.com
4 years ago
With $35M, Whole Biome Eyes 2020 Launch of Medical Food for Diabetes
@xconomy.com
4 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea